LEM S403
Alternative Names: LEM-S403Latest Information Update: 28 Feb 2025
At a glance
- Originator Lemonex
- Class Antineoplastics; Immunotherapies; Oligonucleotides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for preclinical development in Cancer in South Korea (Parenteral)
- 15 Feb 2023 Lemonex plans a clinical trial for Cancer
- 30 Mar 2021 LEM S403 is available for licensing as of 30 Mar 2021. http://www.lemonexbio.com/kwa-2124980#sub4_1